Magnetic nanoparticles in cancer theranostics

Theranostics

Volumn 5, Issue 11, 2015, Pages 1249-1263

  Gobbo, Oliviero L ^a   Sjaastad, Kristine ^b   Radomski, Marek W ^a,c   Volkov, Yuri ^a,b   Prina Mello, Adriele ^a,b  

^a TRINITY COLLEGE DUBLIN   (Ireland)

^b ST JAMES S HOSPITAL   (Ireland)

^c MEDICAL UNIVERSITY OF SILESIA   (Poland)

Author keywords

Cancer; Drug delivery; Magnetic nanoparticles; Theranostic nanomedicine; Thermal therapy

Indexed keywords

AMINOSILICANE; ANTINEOPLASTIC AGENT; GOLD NANOPARTICLE; MAGNETIC NANOPARTICLE; NANOMATERIAL; QUANTUM DOT; SUPERPARAMAGNETIC IRON OXIDE NANOPARTICLE; UNCLASSIFIED DRUG; DRUG CARRIER; FERRIC ION; FERRIC OXIDE; NANOPARTICLE;

AEROSOL; BIOCOMPATIBILITY; CANCER DIAGNOSIS; CANCER GENE THERAPY; CANCER SURVIVAL; CANCER THERAPY; CRYOSURGERY; CRYOTHERAPY; DRUG CYTOTOXICITY; DRUG DELIVERY SYSTEM; DRUG EFFICACY; DRUG RESPONSE; DRUG SAFETY; DRUG TARGETING; EXTERNAL BEAM RADIOTHERAPY; GENE EXPRESSION; GLIOBLASTOMA; HUMAN; HYPERTHERMIC THERAPY; IMAGE ANALYSIS; IMAGE QUALITY; MOLECULAR IMAGING; NANOMEDICINE; NANOTECHNOLOGY; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; PARTICLE SIZE; PERSONALIZED MEDICINE; PHASE 1 CLINICAL TRIAL (TOPIC); PHOTOTHERAPY; PHYSICAL CHEMISTRY; POSITRON EMISSION TOMOGRAPHY; REVIEW; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY; THERANOSTIC NANOMEDICINE; FLUORESCENCE IMAGING; MAGNETISM; NEOPLASMS; PROCEDURES; TRENDS;

DRUG CARRIERS; FERRIC COMPOUNDS; MAGNETICS; NANOPARTICLES; NEOPLASMS; OPTICAL IMAGING; PRECISION MEDICINE; THERANOSTIC NANOMEDICINE;

EID: 84954208048     PISSN: None     EISSN: 18387640     Source Type: Journal    
DOI: 10.7150/thno.11544     Document Type: Review

References (117)

1. [Internet] Feynman RP. http://calteches.library.caltech.edu/1976/1/1960Bottom.pdf.
2. Fu A, Gu W, Larabell C, Alivisatos AP. Semiconductor nanocrystals for biological imaging. Current opinion in neurobiology. 2005; 15: 568-75. doi:10.1016/j.conb.2005.08.004.
3. Bruchez M, Moronne M, Gin P, Weiss S, Alivisatos AP. Semiconductor Nanocrystals as Fluorescent Biological Labels. Science. 1998; 281: 2013-6. doi:10.1126/science.281.5385.2013.
4. Corot C, Robert P, Idee JM, Port M. Recent advances in iron oxide nanocrystal technology for medical imaging. Adv Drug Deliv Rev. 2006; 58: 1471-504. doi:10.1016/j.addr.2006.09.013.
5. Stoll G, Bendszus M. Imaging of inflammation in the peripheral and central nervous system by magnetic resonance imaging. Neuroscience. 2009; 158: 1151-60. doi:10.1016/j.neuroscience.2008.06.045.
6. Vellinga MM, Oude Engberink RD, Seewann A, Pouwels PJ, Wattjes MP, van der Pol SM, et al. Pluriformity of inflammation in multiple sclerosis shown by ultra-small iron oxide particle enhancement. Brain: a journal of neurology. 2008; 131: 800-7. doi:10.1093/brain/awn009.
7. Zhen Z, Xie J. Development of manganese-based nanoparticles as contrast probes for magnetic resonance imaging. Theranostics. 2012; 2: 45-54. doi:10.7150/thno.3448.
8. Sun C, Lee JS, Zhang M. Magnetic nanoparticles in MR imaging and drug delivery. Adv Drug Deliv Rev. 2008; 60: 1252-65. doi:10.1016/j.addr.2008.03.018.
9. Gutwein LG, Webster TJ. Increased viable osteoblast density in the presence of nanophase compared to conventional alumina and titania particles. Biomaterials. 2004; 25: 4175-83. doi:10.1016/j.biomaterials.2003.10.090.
10. Webster T, Ahn E. Nanostructured Biomaterials for Tissue Engineering Bone. In: Lee K, Kaplan D, editors. Tissue Engineering II. Heidelberg: Springer Berlin. 2007: 275-308.
11. Chakraborty M, Jain S, Rani V. Nanotechnology: emerging tool for diagnostics and therapeutics. Applied biochemistry and biotechnology. 2011; 165: 1178-87. doi:10.1007/s12010-011-9336-6.
12. Kateb B, Chiu K, Black KL, Yamamoto V, Khalsa B, Ljubimova JY, et al. Nanoplatforms for constructing new approaches to cancer treatment, imaging, and drug delivery: what should be the policy? NeuroImage. 2011; 54 Suppl 1: S106-24. doi:10.1016/j.neuroimage.2010.01.105.
13. Bhaskar S, Tian F, Stoeger T, Kreyling W, de la Fuente JM, Grazu V, et al. Multifunctional Nanocarriers for diagnostics, drug delivery and targeted treatment across blood-brain barrier: perspectives on tracking and neuroimaging. Particle and fibre toxicology. 2010; 7: 3. doi:10.1186/1743-8977-7-3.
14. Liu C, Zhang N. Nanoparticles in gene therapy principles, prospects, and challenges. Progress in molecular biology and translational science. 2011; 104: 509-62. doi:10.1016/B978-0-12-416020-0.00013-9.
15. Parveen S, Misra R, Sahoo SK. Nanoparticles: a boon to drug delivery, therapeutics, diagnostics and imaging. Nanomedicine-Uk. 2012; 8: 147-66. doi:10.1016/j.nano.2011.05.016.
16. Shenoi MM, Shah NB, Griffin RJ, Vercellotti GM, Bischof JC. Nanoparticle preconditioning for enhanced thermal therapies in cancer. Nanomedicine (Lond). 2011; 6: 545-63. doi:10.2217/nnm.10.153.
17. Shinkai M, Yanase M, Suzuki M, Hiroyuki H, Wakabayashi T, Yoshida J, et al. Intracellular hyperthermia for cancer using magnetite cationic liposomes. Journal of Magnetism and Magnetic Materials. 1999; 194: 176-84. doi:10.1016/S0304-8853(98)00586-1.
18. Kim DH, Nikles DE, Brazel CS. Synthesis and Characterization of Multifunctional Chitosan-MnFe2O4 Nanoparticles for Magnetic Hyperthermia and Drug Delivery. Materials. 2010; 3: 4051-65. doi:10.3390/ma3074051.
19. Zhao Y, Alakhova DY, Kabanov AV. Can nanomedicines kill cancer stem cells? Adv Drug Deliv Rev. 2013; 65: 1763-83. doi:10.1016/j.addr.2013.09.016.
20. Sadhukha T, Niu L, Wiedmann TS, Panyam J. Effective elimination of cancer stem cells by magnetic hyperthermia. Molecular pharmaceutics. 2013; 10: 1432-41. doi:10.1021/mp400015b.
21. Yang C, Xiong F, Wang J, Dou J, Chen J, Chen D, et al. Anti-ABCG2 monoclonal antibody in combination with paclitaxel nanoparticles against cancer stem-like cell activity in multiple myeloma. Nanomedicine (Lond). 2014; 9: 45-60. doi:10.2217/nnm.12.216.
22. Conde J, Dias JT, Grazu V, Moros M, Baptista PV, de la Fuente JM. Revisiting 30 years of biofunctionalization and surface chemistry of inorganic nanoparticles for nanomedicine. Front Chem. 2014; 2: 48. doi:10.3389/fchem.2014.00048.
23. Kievit FM, Zhang M. Surface engineering of iron oxide nanoparticles for targeted cancer therapy. Acc Chem Res. 2011; 44: 853-62. doi:10.1021/ar2000277.
24. Yigit MV, Moore A, Medarova Z. Magnetic nanoparticles for cancer diagnosis and therapy. Pharmaceutical research. 2012; 29: 1180-8. doi:10.1007/s11095-012-0679-7.
25. Movia D, Poland C, Tran L, Volkov Y, Prina-Mello A. Multilayered Nanoparticles for Personalized Medicine: Translation into Clinical Markets. In: Handbook of Clinical Nanomedicine: Nanoparticles, Imaging, Therapy and Clinical Applications Singapore: Pan Stanford Publishing Pte Ltd; 2016.
26. Kumar A, Jena PK, Behera S, Lockey RF, Mohapatra S, Mohapatra S. Multifunctional magnetic nanoparticles for targeted delivery. Nanomedicine-Uk. 2010; 6: 64-9. doi:10.1016/j.nano.2009.04.002.
27. Salas G, Casado C, Teran FJ, Miranda R, Serna CJ, Morales MP. Controlled synthesis of uniform magnetite nanocrystals with high-quality properties for biomedical applications. J Mater Chem. 2012; 22: 21065-75. doi:10.1039/C2JM34402E.
28. Aitziber L. Cortajarena DO, Sandra M. Ocampo, Alberto Gonzalez-Garciá, Pierre Couleaud, Rodolfo Miranda, Cristobal Belda-Iniesta and Angel Ayuso-Sacido. Engineering Iron Oxide Nanoparticles for Clinical Settings. Nanobiomedicine. 2014; 1:2. doi: 10.5772/58841.
29. Ruiz A, Morais P, Bentes de Azevedo R, Lacava ZM, Villanueva A, del Puerto Morales M. Magnetic nanoparticles coated with dimercaptosuccinic acid: development, characterization, and application in biomedicine. J Nanopart Res. 2014; 16: 1-20. doi:10.1007/s11051-014-2589-6.
30. Marciello M, Connord V, Veintemillas-Verdaguer S, Verges MA, Carrey J, Respaud M, et al. Large scale production of biocompatible magnetite nanocrystals with high saturation magnetization values through green aqueous synthesis. Journal of Materials Chemistry B. 2013; 1: 5995-6004. doi:10.1039/C3TB20949K.
31. Gobbo OL, Wetterling F, Vaes P, Teughels S, Markos F, Edge D, et al. Biodistribution and pharmacokinetic studies of SPION using particle electron paramagnetic resonance, MRI and ICP-MS. Nanomedicine-Uk. 2015; 10: 1751-60. doi:10.2217/nnm.15.22.
32. Hilger I, Kaiser WA. Iron oxide-based nanostructures for MRI and magnetic hyperthermia. Nanomedicine-Uk. 2012; 7: 1443-59. doi:10.2217/nnm.12.112.
33. Markides H, Rotherham M, El Haj AJ. Biocompatibility and Toxicity of Magnetic Nanoparticles in Regenerative Medicine. J Nanomater. 2012; 2012: 11. doi:10.1155/2012/614094.
34. Calero M, Gutiérrez L, Salas G, Luengo Y, Lázaro A, Acedo P, et al. Efficient and safe internalization of magnetic iron oxide nanoparticles: Two fundamental requirements for biomedical applications. Nanomedicine: Nanotechnology, Biology and Medicine. 2014; 10: 733-43. doi:http://dx.doi.org/10.1016/j.nano.2013.11.010.
35. Ruiz A, Hernandez Y, Cabal C, Gonzalez E, Veintemillas-Verdaguer S, Martinez E, et al. Biodistribution and pharmacokinetics of uniform magnetite nanoparticles chemically modified with polyethylene glycol. Nanoscale. 2013; 5: 11400-8. doi:10.1039/C3NR01412F.
36. Latorre A, Couleaud P, Aires A, Cortajarena AL, Somoza Á. Multifunctionalization of magnetic nanoparticles for controlled drug release: A general approach. European Journal of Medicinal Chemistry. 2014; 82: 355-62. doi:10.1016/j.ejmech.2014.05.078.
37. Mulens V, Morales MdP, Barber DF. Development of Magnetic Nanoparticles for Cancer Gene Therapy: A Comprehensive Review. ISRN Nanomaterials. 2013; 1: 1-14. doi:10.1155/2013/646284.
38. Arruebo M, Valladares M, Gonzalez-Fernandez A. Antibody-Conjugated Nanoparticles for Biomedical Applications. J Nanomater. 2009; 1: 1-24. doi:10.1155/2009/439389.
39. Destouches D, El Khoury D, Hamma-Kourbali Y, Krust B, Albanese P, Katsoris P, et al. Suppression of Tumor Growth and Angiogenesis by a Specific Antagonist of the Cell-Surface Expressed Nucleolin. PloS one. 2008; 3: e2518. doi:10.1371/journal.pone.0002518.
40. Ventola CL. The Nanomedicine Revolution: Part 1: Emerging Concepts. Pharmacy and Therapeutics. 2012; 37: 512-25.
41. [Internet] WHO/IARC: Lyon, France. World Cancer Report 2008. http://www.iarc.fr/en/publications/pdfs-online/wcr/2008/wcr_2008.pdf.
42. Weissleder R. Molecular imaging in cancer. Science. 2006; 312: 1168-71. doi:10.1126/science.1125949.
43. Condeelis J, Weissleder R. In vivo imaging in cancer. Cold Spring Harbor perspectives in biology. 2010; 2: 1-24. doi:10.1101/cshperspect.a003848.
44. Ambrosone A, Mattera L, Marchesano V, Quarta A, Susha AS, Tino A, et al. Mechanisms underlying toxicity induced by CdTe quantum dots determined in an invertebrate model organism. Biomaterials. 2012; 33: 1991-2000. doi:10.1016/j.biomaterials.2011.11.041.
45. Gobbo OL, Zurek M, Tewes F, Ehrhardt C, Cremillieux Y. Manganese: a new contrast agent for lung imaging? Contrast media & molecular imaging. 2012; 7: 542-6. doi:10.1002/cmmi.1483.
46. Runge VM, Ai T, Hao D, Hu X. The developmental history of the gadolinium chelates as intravenous contrast media for magnetic resonance. Investigative radiology. 2011; 46: 807-16. doi:10.1097/RLI.0b013e318237913b.
47. Aime S, Reineri F. Advances in bio-imaging: a survey from WWMR 2010. Journal of magnetic resonance. 2011; 209: 109-15. doi:10.1016/j.jmr.2011.02.021.
48. Mosbah K, Ruiz-Cabello J, Berthezene Y, Cremillieux Y. Aerosols and gaseous contrast agents for magnetic resonance imaging of the lung. Contrast media & molecular imaging. 2008; 3: 173-90. doi:10.1002/cmmi.252.
49. Rumenapp C, Gleich B, Haase A. Magnetic nanoparticles in magnetic resonance imaging and diagnostics. Pharmaceutical research. 2012; 29: 1165-79. doi:10.1007/s11095-012-0711-y.
50. Na HB, Song IC, Hyeon T. Inorganic Nanoparticles for MRI Contrast Agents. Advanced Materials. 2009; 21: 2133-48. doi:10.1002/adma.200802366.
51. Yallapu MM, Foy SP, Jain TK, Labhasetwar V. PEG-functionalized magnetic nanoparticles for drug delivery and magnetic resonance imaging applications. Pharmaceutical research. 2010; 27: 2283-95. doi:10.1007/s11095-010-0260-1.
52. Hayashi K, Nakamura M, Sakamoto W, Yogo T, Miki H, Ozaki S, et al. Superparamagnetic nanoparticle clusters for cancer theranostics combining magnetic resonance imaging and hyperthermia treatment. Theranostics. 2013; 3: 366-76. doi:10.7150/thno.5860.
53. Zhao Q, Wang L, Cheng R, Mao L, Arnold RD, Howerth EW, et al. Magnetic nanoparticle-based hyperthermia for head & neck cancer in mouse models. Theranostics. 2012; 2: 113-21. doi:10.7150/thno.3854.
54. Peer D, Karp JM, Hong S, Farokhzad OC, Margalit R, Langer R. Nanocarriers as an emerging platform for cancer therapy. Nature nanotechnology. 2007; 2: 751-60. doi:10.1038/nnano.2007.387.
55. Krown SE, Northfelt DW, Osoba D, Stewart JS. Use of liposomal anthracyclines in Kaposi's sarcoma. Seminars in oncology. 2004; 31: 36-52. doi:10.1053/j.seminoncol.2004.08.003.
56. Ranganathan R, Madanmohan S, Kesavan A, Baskar G, Krishnamoorthy YR, Santosham R, et al. Nanomedicine: towards development of patient-friendly drug-delivery systems for oncological applications. International journal of nanomedicine. 2012; 7: 1043-60. doi:10.2147/IJN.S25182.
57. Gaspar MM, Radomska A, Gobbo OL, Bakowsky U, Radomski MW, Ehrhardt C. Targeted delivery of transferrin-conjugated liposomes to an orthotopic model of lung cancer in nude rats. Journal of aerosol medicine and pulmonary drug delivery. 2012; 25: 310-8. doi:10.1089/jamp.2011.0928.
58. Furlani EP. Magnetic Biotransport: Analysis and Applications. Materials. 2010; 3: 2412-46. doi:10.3390/ma3042412.
59. Schlorf T, Meincke M, Kossel E, Gluer CC, Jansen O, Mentlein R. Biological properties of iron oxide nanoparticles for cellular and molecular magnetic resonance imaging. International journal of molecular sciences. 2010; 12: 12-23. doi:10.3390/ijms12010012.
60. Al Faraj A, Lacroix G, Alsaid H, Elgrabi D, Stupar V, Robidel F, et al. Longitudinal 3He and proton imaging of magnetite biodistribution in a rat model of instilled nanoparticles. Magnetic resonance in medicine: official journal of the Society of Magnetic Resonance in Medicine/Society of Magnetic Resonance in Medicine. 2008; 59: 1298-303. doi:10.1002/mrm.21571.
61. Al Faraj A, Bessaad A, Cieslar K, Lacroix G, Canet-Soulas E, Cremillieux Y. Long-term follow-up of lung biodistribution and effect of instilled SWCNTs using multiscale imaging techniques. Nanotechnology. 2010; 21: 175103. doi:10.1088/0957-4484/21/17/175103.
62. Barraud L, Merle P, Soma E, Lefrancois L, Guerret S, Chevallier M, et al. Increase of doxorubicin sensitivity by doxorubicin-loading into nanoparticles for hepatocellular carcinoma cells in vitro and in vivo. Journal of hepatology. 2005; 42: 736-43. doi:10.1016/j.jhep.2004.12.035.
63. Han HD, Mangala LS, Lee JW, Shahzad MM, Kim HS, Shen D, et al. Targeted gene silencing using RGD-labeled chitosan nanoparticles. Clinical cancer research: an official journal of the American Association for Cancer Research. 2010; 16: 3910-22. doi:10.1158/1078-0432.CCR-10-0005.
64. Parveen S, Mitra M, Krishnakumar S, Sahoo SK. Enhanced antiproliferative activity of carboplatin-loaded chitosan-alginate nanoparticles in a retinoblastoma cell line. Acta biomaterialia. 2010; 6: 3120-31. doi:10.1016/j.actbio.2010.02.010.
65. Maeng JH, Lee DH, Jung KH, Bae YH, Park IS, Jeong S, et al. Multifunctional doxorubicin loaded superparamagnetic iron oxide nanoparticles for chemotherapy and magnetic resonance imaging in liver cancer. Biomaterials. 2010; 31: 4995-5006. doi:10.1016/j.biomaterials.2010.02.068.
66. Schwerdt JI, Goya GF, Calatayud MP, Herenu CB, Reggiani PC, Goya RG. Magnetic field-assisted gene delivery: achievements and therapeutic potential. Current gene therapy. 2012; 12: 116-26. doi:10.2174/156652312800099616.
67. Li C, Li L, Keates AC. Targeting cancer gene therapy with magnetic nanoparticles. Oncotarget. 2012; 3: 365-70.
68. Yan JF, Liu J. Nanocryosurgery and its mechanisms for enhancing freezing efficiency of tumor tissues. Nanomedicine-Uk. 2008; 4: 79-87. doi:10.1016/j.nano.2007.11.002.
69. Isbert C, Ritz JP, Roggan A, Schuppan D, Ruhl M, Buhr HJ, et al. Enhancement of the immune response to residual intrahepatic tumor tissue by laser-induced thermotherapy (LITT) compared to hepatic resection. Lasers in surgery and medicine. 2004; 35: 284-92. doi:10.1002/lsm.20097.
70. Ratto F, Matteini P, Centi S, Rossi F, Pini R. Gold nanorods as new nanochromophores for photothermal therapies. Journal of biophotonics. 2011; 4: 64-73. doi:10.1002/jbio.201000002.
71. Kennedy JE, Wu F, ter Haar GR, Gleeson FV, Phillips RR, Middleton MR, et al. High-intensity focused ultrasound for the treatment of liver tumours. Ultrasonics. 2004; 42: 931-5. doi:10.1016/j.ultras.2004.01.089.
72. Kim J, Chung DJ, Jung SE, Cho SH, Hahn ST, Lee JM. Therapeutic effect of high-intensity focused ultrasound combined with transarterial chemoembolisation for hepatocellular carcinoma < 5 cm: comparison with transarterial chemoembolisation monotherapy-preliminary observations. The British journal of radiology. 2012; 85: 940-6. doi:10.1259/bjr/32750755.
73. Chen MH, Yang W, Yan K, Zou MW, Solbiati L, Liu JB, et al. Large liver tumors: protocol for radiofrequency ablation and its clinical application in 110 patients-mathematic model, overlapping mode, and electrode placement process. Radiology. 2004; 232: 260-71. doi:10.1148/radiol.2321030821.
74. Fu Y, Yang W, Wu W, Yan K, Xing BC, Chen MH. Radiofrequency ablation in the management of unresectable intrahepatic cholangiocarcinoma. Journal of vascular and interventional radiology: JVIR. 2012; 23: 642-9. doi:10.1016/j.jvir.2012.01.081.
75. Hilger I, Hergt R, Kaiser WA. Use of magnetic nanoparticle heating in the treatment of breast cancer. IEE proceedings Nanobiotechnology. 2005; 152: 33-9. doi:10.1049/ip-nbt:20055018.
76. Kettering M, Richter H, Wiekhorst F, Bremer-Streck S, Trahms L, Kaiser WA, et al. Minimal-invasive magnetic heating of tumors does not alter intra-tumoral nanoparticle accumulation, allowing for repeated therapy sessions: an in vivo study in mice. Nanotechnology. 2011; 22: 505102. doi:10.1088/0957-4484/22/50/505102.
77. Huang HS, Hainfeld JF. Intravenous magnetic nanoparticle cancer hyperthermia. International journal of nanomedicine. 2013; 8: 2521-32. doi:10.2147/IJN.S43770.
78. Day ES, Morton JG, West JL. Nanoparticles for thermal cancer therapy. Journal of biomechanical engineering. 2009; 131: 074001. doi:10.1115/1.3156800.
79. Huang N, Wang H, Zhao J, Lui H, Korbelik M, Zeng H. Single-wall carbon nanotubes assisted photothermal cancer therapy: animal study with a murine model of squamous cell carcinoma. Lasers in surgery and medicine. 2010; 42: 638-48. doi:10.1002/lsm.20968.
80. Li Y, Dong H, Li Y, Shi D. Graphene-based nanovehicles for photodynamic medical therapy. International journal of nanomedicine. 2015; 10: 2451-9. doi:10.2147/ijn.s68600.
81. [Internet] Magforce. www.magforce.de/fileadmin/magforce/5_presse/presentations/Company_presentation_May2013_English.pdf.
82. Maier-Hauff K, Ulrich F, Nestler D, Niehoff H, Wust P, Thiesen B, et al. Efficacy and safety of intratumoral thermotherapy using magnetic iron-oxide nanoparticles combined with external beam radiotherapy on patients with recurrent glioblastoma multiforme. Journal of neuro-oncology. 2011; 103: 317-24. doi:10.1007/s11060-010-0389-0.
83. Jordan A, Scholz R, Maier-Hauff K, van Landeghem FK, Waldoefner N, Teichgraeber U, et al. The effect of thermotherapy using magnetic nanoparticles on rat malignant glioma. Journal of neuro-oncology. 2006; 78: 7-14. doi:10.1007/s11060-005-9059-z.
84. Johannsen M, Gneveckow U, Taymoorian K, Thiesen B, Waldofner N, Scholz R, et al. Morbidity and quality of life during thermotherapy using magnetic nanoparticles in locally recurrent prostate cancer: results of a prospective phase I trial. International journal of hyperthermia: the official journal of European Society for Hyperthermic Oncology, North American Hyperthermia Group. 2007; 23: 315-23. doi:10.1080/02656730601175479.
85. Veiseh O, Gunn JW, Zhang M. Design and fabrication of magnetic nanoparticles for targeted drug delivery and imaging. Adv Drug Deliv Rev. 2010; 62: 284-304. doi:10.1016/j.addr.2009.11.002.
86. He C, Hu Y, Yin L, Tang C, Yin C. Effects of particle size and surface charge on cellular uptake and biodistribution of polymeric nanoparticles. Biomaterials. 2010; 31: 3657-66. doi:10.1016/j.biomaterials.2010.01.065.
87. Alexiou C, Jurgons R, Seliger C, Brunke O, Iro H, Odenbach S. Delivery of superparamagnetic nanoparticles for local chemotherapy after intraarterial infusion and magnetic drug targeting. Anticancer research. 2007; 27: 2019-22.
88. Tietze R, Lyer S, Durr S, Alexiou C. Nanoparticles for cancer therapy using magnetic forces. Nanomedicine (Lond). 2012; 7: 447-57. doi:10.2217/nnm.12.10.
89. Lubbe AS, Alexiou C, Bergemann C. Clinical applications of magnetic drug targeting. The Journal of surgical research. 2001; 95: 200-6. doi:10.1006/jsre.2000.6030.
90. Dames P, Gleich B, Flemmer A, Hajek K, Seidl N, Wiekhorst F, et al. Targeted delivery of magnetic aerosol droplets to the lung. Nature nanotechnology. 2007; 2: 495-9. doi:10.1038/nnano.2007.217.
91. Fay F, Scott CJ. Antibody-targeted nanoparticles for cancer therapy. Immunotherapy. 2011; 3: 381-94. doi:10.2217/imt.11.5.
92. Arosio D, Casagrande C, Manzoni L. Integrin-mediated drug delivery in cancer and cardiovascular diseases with peptide-functionalized nanoparticles. Current medicinal chemistry. 2012; 19: 3128-51. doi:10.2174/092986712800784748.
93. Huang R, Han L, Li J, Liu S, Shao K, Kuang Y, et al. Chlorotoxin-modified macromolecular contrast agent for MRI tumor diagnosis. Biomaterials. 2011; 32: 5177-86. doi:10.1016/j.biomaterials.2011.03.075.
94. Destouches D, Page N, Hamma-Kourbali Y, Machi V, Chaloin O, Frechault S, et al. A simple approach to cancer therapy afforded by multivalent pseudopeptides that target cell-surface nucleoproteins. Cancer research. 2011; 71: 3296-305. doi:10.1158/0008-5472.CAN-10-3459.
95. Manke A, Wang L, Rojanasakul Y. Mechanisms of nanoparticle-induced oxidative stress and toxicity. BioMed research international. 2013; 1: 942916. doi:10.1155/2013/942916.
96. Mahmoudi M, Hofmann H, Rothen-Rutishauser B, Petri-Fink A. Assessing the in vitro and in vivo toxicity of superparamagnetic iron oxide nanoparticles. Chemical reviews. 2012; 112: 2323-38. doi:10.1021/cr2002596.
97. Ehmann F, Sakai-Kato K, Duncan R, Hernan Perez de la Ossa D, Pita R, Vidal JM, et al. Next-generation nanomedicines and nanosimilars: EU regulators' initiatives relating to the development and evaluation of nanomedicines. Nanomedicine (Lond). 2013; 8: 849-56. doi:10.2217/nnm.13.68.
98. [Internet] European Medicines Agency. Regulatory and procedural guideline. 2009. http://www.ema.europa.eu/docs/en_GB/document_library/Regulatory_and_procedural_guideline/2009/10/WC500004481.pdf.
99. [Internet] EU legislation on medical devices: Guidance document. 2012. http://ec.europa.eu/health/medical-devices/files/meddev/2_1_6_ol_en.pdf .
100. [Internet] AFSSAPS: Recommandations for toxicological evaluation of nanoparticle medicinal products. 2011. http://ansm.sante.fr/var/ansm_site/storage/original/application/2968a90b774b563b03405379b7d4f4e6.pdf.
101. Mahmoudi M, Simchi A, Imani M, Shokrgozar MA, Milani AS, Hafeli UO, et al. A new approach for the in vitro identification of the cytotoxicity of superparamagnetic iron oxide nanoparticles. Colloids and surfaces B, Biointerfaces. 2010; 75: 300-9. doi:10.1016/j.colsurfb.2009.08.044.
102. [Internet] European Medicines Agency: Reflection paper on non-clinical studies for generic nanoparticle iron medicinal product applications. 2011. http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2011/04/WC500105048.pdf.
103. [Internet] European Medicines Agency: Reflection paper on surface coatings: general issues for consideration regarding parenteral administration of coated nanomedicine products. 2013. http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2013/08/WC500147874.pdf.
104. [Internet] European Medicines Agency: Guideline on clinical evaluation of diagnostic agents. 2009. http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2009/09/WC500003580.pdf.
105. Ahmed N, Fessi H, Elaissari A. Theranostic applications of nanoparticles in cancer. Drug discovery today. 2012; 17: 928-34. doi:10.1016/j.drudis.2012.03.010.
106. Liu Y, Zhang N. Gadolinium loaded nanoparticles in theranostic magnetic resonance imaging. Biomaterials. 2012; 33: 5363-75. doi:10.1016/j.biomaterials.2012.03.084.
107. Xu H, Cheng L, Wang C, Ma X, Li Y, Liu Z. Polymer encapsulated upconversion nanoparticle/iron oxide nanocomposites for multimodal imaging and magnetic targeted drug delivery. Biomaterials. 2011; 32: 9364-73. doi:10.1016/j.biomaterials.2011.08.053.
108. Hayashi K, Nakamura M, Miki H, Ozaki S, Abe M, Matsumoto T, et al. Magnetically responsive smart nanoparticles for cancer treatment with a combination of magnetic hyperthermia and remote-control drug release. Theranostics. 2014; 4: 834-44. doi:10.7150/thno.9199.
109. [Internet] European Technological Platform on Nanomedicine: European Funding allocated to Nanomedicine-related projects. 2015. http://www.etp-nanomedicine.eu/public/about-nanomedicine/european-funding.
110. [Internet] The European Technology Platform on Nanomedicine. 2014. http://www.etp-nanomedicine.eu/public.
111. Nofiele JT, Haedicke IE, Zhu Yle K, Zhang XA, Cheng HL. Gadolinium-free extracellular MR contrast agent for tumor imaging. Journal of magnetic resonance imaging: JMRI. 2015; 41: 397-403. doi:10.1002/jmri.24561.
112. Kuo PH, Kanal E, Abu-Alfa AK, Cowper SE. Gadolinium-based MR contrast agents and nephrogenic systemic fibrosis. Radiology. 2007; 242: 647-9. doi:10.1148/radiol.2423061640.
113. Longmire M, Choyke PL, Kobayashi H. Clearance properties of nano-sized particles and molecules as imaging agents: considerations and caveats. Nanomedicine (Lond). 2008; 3: 703-17. doi:10.2217/17435889.3.5.703.
114. Prince MR, Zhang HL, Roditi GH, Leiner T, Kucharczyk W. Risk factors for NSF: a literature review. Journal of magnetic resonance imaging: JMRI. 2009; 30: 1298-308. doi:10.1002/jmri.21973.
115. Bau M, Dulski P. Anthropogenic origin of positive gadolinium anomalies in river waters. Earth and Planetary Science Letters. 1996; 143: 245-55. doi:10.1016/0012-821X(96)00127-6.
116. Elbaz-Poulichet F, Seidel JL, Othoniel C. Occurrence of an anthropogenic gadolinium anomaly in river and coastal waters of southern France. Water research. 2002; 36: 1102-5. doi:10.1016/S0043-1354(01)00370-0.
117. [Internet] European Technological Platform on Nanomedicine: Nanomedicine 2020. White paper to the horizon 2020 Framework Programme for Research and Innovation. 2013. http://www.etp-nanomedicine.eu/public/press-documents/publications/etpn-publications/etpn-white-paper-H2020.